14 Perspectives of Aptamers for Medical Applications
459
studies in mice bearing C26 colon carcinoma. Nanoscale Res Lett 15(1):101. https://doi.org/
10.1186/s11671-020-03334-9
202. Zhao Y, Xu J, Le VM, Gong Q, Li S, Gao F, Ni L, Liu J, Liang X (2019) EpCAM aptamerfunctionalized cationic liposome-based nanoparticles loaded with miR-139-5p for targeted
therapy in colorectal cancer. Mol Pharm 16(11):4696–4710. https://doi.org/10.1021/acs.mol
pharmaceut.9b00867
203. Kim JK, Choi KJ, Lee M, Jo MH, Kim S (2012) Molecular imaging of a cancer-targeting
theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beaconconjugated nanoparticle. Biomaterials 33(1):207–217. https://doi.org/10.1016/j.biomaterials.
2011.09.023
204. Marcuello M, Vymetalkova V, Neves RPL, Duran-Sanchon S, Vedeld HM, Tham E, van
Dalum G, Flügen G, Garcia-Barberan V, Fijneman RJ, Castells A, Vodicka P, Lind GE,
Stoecklein NH, Heitzer E, Gironella M (2019) Circulating biomarkers for early detection and
clinical management of colorectal cancer. Mol Aspects Med 69:107–122. https://doi.org/10.
1016/j.mam.2019.06.002
205. Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardio
vascular-diseases-(cvds)
206. Vavalle JP, Cohen MG (2012) The REG1 anticoagulation system: a novel actively controlled
factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome.
Future Cardiol 8(3):371–382. https://doi.org/10.2217/fca.12.5
207. Ponce AT, Hong KL (2019) A Mini-Review: clinical development and potential of aptamers
for thrombotic events treatment and monitoring. Biomedicines 7(3). https://doi.org/10.3390/
biomedicines7030055
208. Jilma-Stohlawetz P, Gilbert JC, Gorczyca ME, Knöbl P, Jilma B (2011) A dose ranging phase
I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital
thrombotic thrombocytopenic purpura. Thromb Haemost 106(3):539–547. https://doi.org/10.
1160/th11-02-0069
209. Jilma B, Paulinska P, Jilma-Stohlawetz P, Gilbert JC, Hutabarat R, Knöbl P (2010) A
randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with
type 2b von Willebrand disease. Thromb Haemost 104(3):563–570. https://doi.org/10.1160/
th10-01-0027
210. Jilma-Stohlawetz P, Knöbl P, Gilbert JC, Jilma B (2012) The anti-von Willebrand factor
aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with
type 2B von Willebrand disease. Thromb Haemost 108(2):284–290. https://doi.org/10.1160/
th11-12-0889
211. Study of NU172 as Anticoagulation in Patients Undergoing Off-pump CABG Surgery
(SNAP-CABG-OFF). ClinicalTrials.gov Identifier: NCT00808964. https://clinicaltrials.gov/
ct2/show/NCT00808964?term=NCT00808964&draw=2&rank=1
212. Dyke CK, Steinhubl SR, Kleiman NS, Cannon RO, Aberle LG, Lin M, Myles SK, Melloni C,
Harrington RA, Alexander JH, Becker RC, Rusconi CP (2006) First-in-human experience of
an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
Circulation 114(23):2490–2497. https://doi.org/10.1161/circulationaha.106.668434
213. Cohen MG, Purdy DA, Rossi JS, Grinfeld LR, Myles SK, Aberle LH, Greenbaum AB, Fry E,
Chan MY, Tonkens RM, Zelenkofske S, Alexander JH, Harrington RA, Rusconi CP, Becker
RC (2010) First clinical application of an actively reversible direct factor IXa inhibitor
as an anticoagulation strategy in patients undergoing percutaneous coronary intervention.
Circulation 122(6):614–622. https://doi.org/10.1161/circulationaha.109.927756
214. Povsic TJ, Wargin WA, Alexander JH, Krasnow J, Krolick M, Cohen MG, Mehran R, Buller
CE, Bode C, Zelenkofske SL, Rusconi CP, Becker RC (2011) Pegnivacogin results in near
complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and
pharmacodynamic substudy. Eur Heart J 32(19):2412–2419. https://doi.org/10.1093/eurhea
rtj/ehr179
459
studies in mice bearing C26 colon carcinoma. Nanoscale Res Lett 15(1):101. https://doi.org/
10.1186/s11671-020-03334-9
202. Zhao Y, Xu J, Le VM, Gong Q, Li S, Gao F, Ni L, Liu J, Liang X (2019) EpCAM aptamerfunctionalized cationic liposome-based nanoparticles loaded with miR-139-5p for targeted
therapy in colorectal cancer. Mol Pharm 16(11):4696–4710. https://doi.org/10.1021/acs.mol
pharmaceut.9b00867
203. Kim JK, Choi KJ, Lee M, Jo MH, Kim S (2012) Molecular imaging of a cancer-targeting
theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beaconconjugated nanoparticle. Biomaterials 33(1):207–217. https://doi.org/10.1016/j.biomaterials.
2011.09.023
204. Marcuello M, Vymetalkova V, Neves RPL, Duran-Sanchon S, Vedeld HM, Tham E, van
Dalum G, Flügen G, Garcia-Barberan V, Fijneman RJ, Castells A, Vodicka P, Lind GE,
Stoecklein NH, Heitzer E, Gironella M (2019) Circulating biomarkers for early detection and
clinical management of colorectal cancer. Mol Aspects Med 69:107–122. https://doi.org/10.
1016/j.mam.2019.06.002
205. Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardio
vascular-diseases-(cvds)
206. Vavalle JP, Cohen MG (2012) The REG1 anticoagulation system: a novel actively controlled
factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome.
Future Cardiol 8(3):371–382. https://doi.org/10.2217/fca.12.5
207. Ponce AT, Hong KL (2019) A Mini-Review: clinical development and potential of aptamers
for thrombotic events treatment and monitoring. Biomedicines 7(3). https://doi.org/10.3390/
biomedicines7030055
208. Jilma-Stohlawetz P, Gilbert JC, Gorczyca ME, Knöbl P, Jilma B (2011) A dose ranging phase
I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital
thrombotic thrombocytopenic purpura. Thromb Haemost 106(3):539–547. https://doi.org/10.
1160/th11-02-0069
209. Jilma B, Paulinska P, Jilma-Stohlawetz P, Gilbert JC, Hutabarat R, Knöbl P (2010) A
randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with
type 2b von Willebrand disease. Thromb Haemost 104(3):563–570. https://doi.org/10.1160/
th10-01-0027
210. Jilma-Stohlawetz P, Knöbl P, Gilbert JC, Jilma B (2012) The anti-von Willebrand factor
aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with
type 2B von Willebrand disease. Thromb Haemost 108(2):284–290. https://doi.org/10.1160/
th11-12-0889
211. Study of NU172 as Anticoagulation in Patients Undergoing Off-pump CABG Surgery
(SNAP-CABG-OFF). ClinicalTrials.gov Identifier: NCT00808964. https://clinicaltrials.gov/
ct2/show/NCT00808964?term=NCT00808964&draw=2&rank=1
212. Dyke CK, Steinhubl SR, Kleiman NS, Cannon RO, Aberle LG, Lin M, Myles SK, Melloni C,
Harrington RA, Alexander JH, Becker RC, Rusconi CP (2006) First-in-human experience of
an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
Circulation 114(23):2490–2497. https://doi.org/10.1161/circulationaha.106.668434
213. Cohen MG, Purdy DA, Rossi JS, Grinfeld LR, Myles SK, Aberle LH, Greenbaum AB, Fry E,
Chan MY, Tonkens RM, Zelenkofske S, Alexander JH, Harrington RA, Rusconi CP, Becker
RC (2010) First clinical application of an actively reversible direct factor IXa inhibitor
as an anticoagulation strategy in patients undergoing percutaneous coronary intervention.
Circulation 122(6):614–622. https://doi.org/10.1161/circulationaha.109.927756
214. Povsic TJ, Wargin WA, Alexander JH, Krasnow J, Krolick M, Cohen MG, Mehran R, Buller
CE, Bode C, Zelenkofske SL, Rusconi CP, Becker RC (2011) Pegnivacogin results in near
complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and
pharmacodynamic substudy. Eur Heart J 32(19):2412–2419. https://doi.org/10.1093/eurhea
rtj/ehr179